
Patrick J Grohar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2908124/publications.pdf Version: 2024-02-01



PATRICK | CROHAR

#	Article	IF	CITATIONS
1	Ewing sarcoma and related <scp>FET</scp> family translocationâ€associated round cell tumors: A century of clinical and scientific progress. Genes Chromosomes and Cancer, 2022, 61, 509-517.	2.8	5
2	Lurbinectedin Inhibits the EWS–WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor. Molecular Cancer Therapeutics, 2022, 21, 1296-1305.	4.1	8
3	Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children's Oncology Group study AEWS0031 Journal of Clinical Oncology, 2022, 40, 11505-11505.	1.6	2
4	A report on the review of archived osteosarcoma and EWING sarcoma specimens at the Biopathology Center, BONE Sarcoma Committee, Children's Oncology Group Journal of Clinical Oncology, 2022, 40, 11524-11524.	1.6	1
5	Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatric Blood and Cancer, 2021, 68, e29188.	1.5	7
6	Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. EMBO Molecular Medicine, 2021, 13, e12640.	6.9	7
7	One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma. Journal of Bone Oncology, 2021, 31, 100404.	2.4	12
8	Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma, 2020, 2020, 1-9.	1.3	12
9	Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. Clinical Cancer Research, 2019, 25, 3417-3429.	7.0	32
10	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript. Cancer Chemotherapy and Pharmacology, 2017, 80, 645-652.	2.3	54
11	Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clinical Cancer Research, 2016, 22, 4105-4118.	7.0	56
12	Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Research, 2016, 76, 6657-6668.	0.9	57
13	18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FL1 Activity and Ewing Sarcoma. Scientific Reports, 2016, 6, 33926.	3.3	10
14	Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma. Cell Reports, 2016, 14, 598-610.	6.4	53
15	Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth. Clinical Cancer Research, 2014, 20, 1190-1203.	7.0	64
16	Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells. Neoplasia, 2011, 13, 145-IN10.	5.3	103
17	Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening. Journal of the National Cancer Institute, 2011, 103, 962-978.	6.3	174